On the fly News and insights, exclusive to thefly.com

IMV

IMV Inc.

$5.17 /

+2.19 (+73.49%)

10:41
07/14/20
07/14
10:41
07/14/20
10:41

IMV Inc. price target raised to $11 from $8.50 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised the firm's price target on IMV Inc. to $11 from $8.50 and reiterates an Overweight rating on the shares. The stock in morning trading is up 79%, or $2.37, to $5.37. IMV announced an agreement with Health Canada for a Phase 1 trial of SARS-CoV-2 vaccine candidate, DPX-COVID-19, in 84 healthy volunteers, Birchenough tells investors in a research note. Following the news, the analyst increased the probability of success for DPX-COVID-19 to 65%. He views IMV as attractively valued relative to vaccine peers and sees further upside potential on broader development and/or a partnership beyond Canada.

IMV IMV Inc.
$5.17 /

+2.19 (+73.49%)

05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
05/15/20 H.C. Wainwright
IMV Inc. price target raised to $13 from $11.50 at H.C. Wainwright
04/01/20 B. Riley FBR
IMV Inc. downgraded to Neutral from Buy at B. Riley FBR

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.